News
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...
CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
1d
Adweek on MSNEli Lilly's Big Task: Become a Loved and Trusted Pharma BrandHealthcare professionals who "do exceptional things" and "refuse to accept medicine as it is." Those who are "unsatisfied, ...
Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...
1d
Zacks Investment Research on MSNEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItEli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results